Výsledky vyhledávání - "Galaktia Kallergi"

Abstract 1966: Dr

Autor: Argyro Roumeliotou, Evangelia Pantazaka, Anastasia Xagara, Thomas Makatsoris, Angelos Koutras, Vassilis Georgoulias, Athanasios Kotsakis, Galaktia Kallergi

Publikováno v: Cancer Research. 82:1966-1966

Background: According to recent publications of our group, JUNB and CXCR4 were overexpressed in CTCs and DTCs isolated from breast cancer patients. This expression was related with patients’ clinical outcome. Current study investigates for the firs

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::577facb59e92caae5be5c0ccdf461659
https://doi.org/10.1158/1538-7445.am2022-1966

Zobrazit plný text záznamu

Evaluation of α-tubulin, detyrosinated α-tubulin, and vimentin in CTCs: identification of the interaction between CTCs and blood cells through cytoskeletal elements

Autor: Stuart S. Martin, Despoina Aggouraki, V. Georgoulias, Christos Stournaras, Galaktia Kallergi, Nefeli Zacharopoulou

Publikováno v: Breast Cancer Research : BCR
Breast Cancer Research, Vol 20, Iss 1, Pp 1-13 (2018)

Background Circulating tumor cells (CTCs) are the major players in the metastatic process. A potential mechanism of cell migration and invasion is the formation of microtentacles in tumor cells. These structures are supported by α-tubulin (TUB), det

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e8f161b2086353fe8fc9653cda95e3d
https://pubmed.ncbi.nlm.nih.gov/29976237

Zobrazit plný text záznamu

Abstract 2397: Evaluation of proliferation and apoptosis markers in circulating tumor cells (CTCs) of women with early breast cancer who are candidates for tumor dormancy

Autor: Dimitrios Mavroudis, Maria Spiliotaki, Vassilis Georgoulias, Sofia Agelaki, Harris Markomanolaki, Galaktia Kallergi, Maria Papadaki

Publikováno v: Cancer Research. 72:2397-2397

Background: In breast cancer (BC) recurrences frequently occur many years after removal of the primary tumor. These relapses are thought to originate from cells that disseminated from the primary tumor and underwent a period of inactivity, called tum

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2cc878619ce3ee06720d68418089f608
https://doi.org/10.1158/1538-7445.am2012-2397

Zobrazit plný text záznamu

Abstract 3411: A pilot feasibility study to evaluate the efficacy of lapatinib in the elimination of HER2-positive circulating tumor cells in peripheral blood of women with metastatic breast cancer

Autor: Galaktia Kallergi, Harris Markomanolaki, Sofia Agelaki, Antonia Kalykaki, Dimitrios Mavroudis, Konstantinos Kalbakis, Vassilis Georgoulias

Publikováno v: Cancer Research. 72:3411-3411

Background: The monitoring of circulating tumor cells (CTCs) detected in peripheral blood (PB) of patients (pts) with metastatic breast cancer (BC) has been proven a potent prognostic tool. CTCs detected after the completion of therapy are theoretica

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::93d779bea78cb76ca84a3853d859f136
https://doi.org/10.1158/1538-7445.am2012-3411

Zobrazit plný text záznamu

Abstract 2387: Analysis of the expression of stemness and epithelial-to-mesenchymal transition markers in circulating tumor cells of patients with breast cancer

Autor: Maria Papadaki, Galaktia Kallergi, Panayiotis A. Theodoropoulos, Sofia Agelaki, Dimitrios Mavroudis, Vassilis Georgoulias, Hara Polioudaki

Publikováno v: Cancer Research. 72:2387-2387

Introduction: Circulating tumor cells (CTCs) have been identified in peripheral blood (PB) of patients with breast cancer and their presence has been associated with poor disease outcome. Cancer is considered to be driven by cancer stem cells (CSCs)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b544bc3f4f132524ae9a855111871dea
https://doi.org/10.1158/1538-7445.am2012-2387

Zobrazit plný text záznamu

Abstract 2379: Expression of truncated HER2 receptor in circulating tumor cells (CTCs) of breast cancer patients

Autor: Galaktia Kallergi, Dimitris Mavroudis, Maria Papadaki, Sophia Agelaki, Vassilis Georgoulias, Dimitris Nasias

Publikováno v: Cancer Research. 72:2379-2379

Introduction: HER2 receptor is overexpressed in 15-25% of patients with breast cancer. In HER2 positive breast cancer the administration of trastuzumab has changed the outcome of disease. However, most patients will eventually develop resistance to t

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7df1f4e272448105b78a4e509ff46b2e
https://doi.org/10.1158/1538-7445.am2012-2379

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání